NO20061479L - Anvendelse av modifiserte cyklosporiner for behandling av HCV-forstyrrelser - Google Patents
Anvendelse av modifiserte cyklosporiner for behandling av HCV-forstyrrelserInfo
- Publication number
- NO20061479L NO20061479L NO20061479A NO20061479A NO20061479L NO 20061479 L NO20061479 L NO 20061479L NO 20061479 A NO20061479 A NO 20061479A NO 20061479 A NO20061479 A NO 20061479A NO 20061479 L NO20061479 L NO 20061479L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- cyclosporins
- hcv
- disorders
- modified
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0320638.0A GB0320638D0 (en) | 2003-09-03 | 2003-09-03 | Organic compounds |
PCT/EP2004/009804 WO2005021028A1 (en) | 2003-09-03 | 2004-09-02 | Use of modified cyclosporins for the treatment of hcv disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20061479L true NO20061479L (no) | 2006-06-02 |
Family
ID=28686843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20061479A NO20061479L (no) | 2003-09-03 | 2006-03-31 | Anvendelse av modifiserte cyklosporiner for behandling av HCV-forstyrrelser |
Country Status (30)
Country | Link |
---|---|
US (1) | US7968518B2 (ko) |
EP (2) | EP1663287B1 (ko) |
JP (1) | JP4688806B2 (ko) |
KR (1) | KR101116968B1 (ko) |
CN (1) | CN1842343A (ko) |
AU (2) | AU2004268382A1 (ko) |
BR (1) | BRPI0414062B8 (ko) |
CA (1) | CA2537137C (ko) |
CY (1) | CY1110506T1 (ko) |
DE (1) | DE602004022061D1 (ko) |
DK (1) | DK1663287T3 (ko) |
ES (1) | ES2328361T3 (ko) |
GB (1) | GB0320638D0 (ko) |
HK (1) | HK1091732A1 (ko) |
HR (1) | HRP20090535T1 (ko) |
IL (1) | IL173909A (ko) |
IS (1) | IS2917B (ko) |
MA (1) | MA28032A1 (ko) |
MX (1) | MXPA06002394A (ko) |
NO (1) | NO20061479L (ko) |
NZ (1) | NZ545495A (ko) |
PL (1) | PL1663287T3 (ko) |
PT (1) | PT1663287E (ko) |
RU (1) | RU2389501C2 (ko) |
SG (1) | SG149063A1 (ko) |
SI (1) | SI1663287T1 (ko) |
TN (1) | TNSN06071A1 (ko) |
TW (1) | TWI342782B (ko) |
WO (1) | WO2005021028A1 (ko) |
ZA (1) | ZA200601550B (ko) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9911724A (pt) | 1998-07-01 | 2001-03-20 | Debiopharm Sa | Ciclosporina que tem um perfil de atividade melhorado |
GB0320638D0 (en) | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
GB0500020D0 (en) * | 2005-01-04 | 2005-02-09 | Novartis Ag | Organic compounds |
MX2007000503A (es) * | 2004-07-14 | 2007-03-08 | Novartis Ag | Uso de una combinacion de ciclosporina e interferon pegilado para el tratamiento de hepatitis c(hcv). |
US7196161B2 (en) | 2004-10-01 | 2007-03-27 | Scynexis Inc. | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection |
SG139750A1 (en) * | 2004-10-01 | 2008-02-29 | Debiopharm Sa Ch | Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3- [etval]4-cyclosporin |
SI1802650T1 (sl) * | 2004-10-01 | 2012-03-30 | Scynexis Inc | Eter in tioeter substituirani ciklosporinski derivati za zdravljenje in preventivo pred infekcijami s hepatitisom c |
ATE412005T1 (de) | 2004-11-22 | 2008-11-15 | Astellas Pharma Inc | Zyklosporinanalog |
JP2008525458A (ja) * | 2004-12-23 | 2008-07-17 | ノバルティス アクチエンゲゼルシャフト | フラビウイルス科処置用化合物 |
NZ555143A (en) * | 2004-12-23 | 2009-12-24 | Novartis Ag | Compositions for HCV treatment |
CN101242842A (zh) | 2005-06-17 | 2008-08-13 | 诺瓦提斯公司 | Sanglifehrin在hcv中的用途 |
CN101316606B (zh) * | 2005-09-30 | 2015-05-27 | 西尼克斯公司 | 治疗和预防丙型肝炎感染的方法和药物组合物 |
RU2440822C2 (ru) * | 2005-09-30 | 2012-01-27 | Скайнексис, Инк | Способы и фармацевтические композиции для лечения и профилактики инфекции гепатита с |
CA2623864C (en) | 2005-09-30 | 2014-12-16 | Scynexis, Inc. | Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection |
US7872097B2 (en) * | 2005-10-26 | 2011-01-18 | Astellas Pharma Inc. | Cyclic peptide compounds |
US7696165B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
US7696166B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
DK2023918T3 (da) | 2006-05-19 | 2011-04-26 | Scynexis Inc | Cyclosporiner til behandlingen og forebyggelse af okulære lidelser |
WO2007141395A1 (fr) * | 2006-06-02 | 2007-12-13 | Claude Annie Perrichon | Gestion des electrons actifs |
RU2463071C2 (ru) * | 2006-10-12 | 2012-10-10 | Новартис Аг | Применение модифицированных циклоспоринов |
WO2008069917A2 (en) * | 2006-11-20 | 2008-06-12 | Scynexis, Inc. | Novel cyclic peptides |
JP5801534B2 (ja) * | 2007-01-04 | 2015-10-28 | デビオファーム インターナショナル ソシエテ アノニム | ウールリッヒ型先天筋ジストロフィーの処置のための、非免疫抑制性シクロスポリン |
MX2009011512A (es) * | 2007-05-02 | 2009-11-12 | Astellas Pharma Inc | Nuevos compuestos peptidos ciclicos. |
EP2193807A4 (en) * | 2007-08-24 | 2012-09-12 | Univ Sapporo Medical | BINDING PROTEIN AT CYCLOSPORIN A |
US20090306033A1 (en) * | 2008-06-06 | 2009-12-10 | Keqiang Li | Novel cyclic peptides |
EP2280989B1 (en) | 2008-06-06 | 2016-02-10 | Scynexis, Inc. | Cyclosporin analogs and their use in the treatment of hcv infections |
WO2010012073A1 (en) * | 2008-07-30 | 2010-02-04 | Isotechnika Labs Inc. | Nonimmunosuppressive cyclosporine analogue molecules |
WO2010035722A1 (ja) * | 2008-09-24 | 2010-04-01 | アステラス製薬株式会社 | ペプチド化合物およびその製造方法 |
AU2009312535B2 (en) * | 2008-11-06 | 2015-03-26 | Debio Recherche Pharmaceutique S.A. | Cycloundecadepsipeptide compounds and use of said compounds as a medicament |
CA2748389A1 (en) * | 2008-12-31 | 2010-07-08 | Scynexis, Inc. | Derivatives of cyclosporin a |
KR101476626B1 (ko) | 2009-01-30 | 2014-12-26 | 이난타 파마슈티칼스, 인코포레이티드 | C형 간염을 예방하거나 치료하기 위한 사이클로스포린 유사체 |
US8481483B2 (en) | 2009-02-19 | 2013-07-09 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues |
US8685917B2 (en) | 2009-07-09 | 2014-04-01 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues |
US8367053B2 (en) | 2009-07-09 | 2013-02-05 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues |
US8349312B2 (en) | 2009-07-09 | 2013-01-08 | Enanta Pharmaceuticals, Inc. | Proline substituted cyclosporin analogues |
US20110117055A1 (en) | 2009-11-19 | 2011-05-19 | Macdonald James E | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds |
CA2782898A1 (en) | 2009-12-09 | 2011-06-16 | Scynexis, Inc. | Novel cyclic peptides |
US8623814B2 (en) | 2010-02-23 | 2014-01-07 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
AR083337A1 (es) | 2010-10-05 | 2013-02-21 | Novartis Ag | Tratamientos de infeccion por el virus de hepatitis c |
US20130251678A1 (en) | 2010-11-30 | 2013-09-26 | Novartis Ag | Bid dosage regimen for deb025 |
JO3337B1 (ar) | 2010-12-13 | 2019-03-13 | Debiopharm Sa | تركيبات صيدلية تشمل أليسبوريفير |
MY192981A (en) | 2010-12-15 | 2022-09-20 | Contravir Pharmaceuticals Inc | Cyclosporine analogue molecules modified at amino acid 1 and 3 |
CN105749246A (zh) | 2011-03-31 | 2016-07-13 | 诺华股份有限公司 | 治疗丙肝病毒感染的阿拉泊韦 |
EP2694087B1 (en) | 2011-04-01 | 2015-01-28 | Novartis AG | Treatment for infection with hepatitis b virus alone or in combination with hepatitis delta virus and associated liver diseases |
WO2012140082A1 (en) | 2011-04-13 | 2012-10-18 | Novartis Ag | Treatment of hepatitis c virus infection with alisporivir |
MX2014003753A (es) | 2011-09-27 | 2014-05-01 | Novartis Ag | Alisporivir para el tratamiento de la infeccion por virus de la hepatitis c. |
KR20150013152A (ko) | 2012-05-07 | 2015-02-04 | 노파르티스 아게 | 알리스포리비르를 이용한 약동학적 조절 |
EP3263587A1 (en) | 2012-06-01 | 2018-01-03 | Allergan, Inc. | Cyclosporin a analogs |
WO2014085623A1 (en) | 2012-11-28 | 2014-06-05 | Enanta Pharmaceuticals, Inc. | Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues |
WO2015008223A1 (en) | 2013-07-17 | 2015-01-22 | Novartis Ag | Treatment of hepatitis c virus infection with alisporivir and ribavirin |
CA2921961A1 (en) | 2013-08-26 | 2015-03-05 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues for preventing or treating hepatitis c |
WO2015136455A1 (en) | 2014-03-13 | 2015-09-17 | Novartis Ag | New treatments of hepatitis c virus infection |
US9669095B2 (en) | 2014-11-03 | 2017-06-06 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues for preventing or treating hepatitis C infection |
WO2016112321A1 (en) | 2015-01-08 | 2016-07-14 | Allergan, Inc. | Cyclosporin derivatives wherein the mebmt sidechain has been cyclized |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5639724A (en) * | 1984-07-24 | 1997-06-17 | Sandoz Ltd. | Cyclosporin galenic forms |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
JP2514950B2 (ja) | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | 化学修飾蛋白質,その製造法および中間体 |
GB2222770B (en) | 1988-09-16 | 1992-07-29 | Sandoz Ltd | Pharmaceutical compositions containing cyclosporins |
DK0484281T4 (da) * | 1990-11-02 | 2001-02-05 | Novartis Ag | Cyclosporiner |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
US6174868B1 (en) * | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
JP2579602B2 (ja) | 1992-10-21 | 1997-02-05 | 吉富製薬株式会社 | 2−アミノ−1,3−プロパンジオール化合物および免疫抑制剤 |
PT730470E (pt) | 1993-11-10 | 2002-08-30 | Enzon Inc | Conjugados melhorados de interferao-polimero |
ATE211726T1 (de) | 1994-08-22 | 2002-01-15 | Welfide Corp | Benzolderivate und deren medizinische verwendung |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
JP3786447B2 (ja) * | 1995-03-31 | 2006-06-14 | エーザイ株式会社 | C型肝炎の予防・治療剤 |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
FR2757522B1 (fr) | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
FR2757520B1 (fr) | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent |
FR2757521B1 (fr) * | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
IL155066A (en) | 1997-04-04 | 2004-06-20 | Mitsubishi Pharma Corp | History 2 - Amino - 2 - (2 - Ethyl (converted)) Propane - 1, 3 - Diol Efficacy in the preparation of 2 - Aminopropene - 1, 3 - Diol |
JPH1180026A (ja) | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
GB9811854D0 (en) * | 1998-06-02 | 1998-07-29 | Ciba Geigy Ag | Organic compounds |
BR9911724A (pt) | 1998-07-01 | 2001-03-20 | Debiopharm Sa | Ciclosporina que tem um perfil de atividade melhorado |
CN1267429C (zh) | 2000-07-13 | 2006-08-02 | 三共株式会社 | 氨基醇衍生物 |
JP2004507552A (ja) | 2000-08-31 | 2004-03-11 | メルク エンド カムパニー インコーポレーテッド | 免疫調節剤としてのリン酸誘導体 |
CA2426381A1 (en) * | 2000-10-19 | 2002-04-25 | Fujisawa Pharmaceutical Co., Ltd. | Cell damage inhibitor |
JP2002125683A (ja) * | 2000-10-27 | 2002-05-08 | Tokyoto Igaku Kenkyu Kiko | インターフェロンの有効性を予測する方法並びにそれに用いられるプライマー及びプローブ |
ATE314383T1 (de) | 2001-03-26 | 2006-01-15 | Novartis Pharma Gmbh | 2-amino-propanol derivate |
JP2002316985A (ja) | 2001-04-20 | 2002-10-31 | Sankyo Co Ltd | ベンゾチオフェン誘導体 |
US6960692B2 (en) | 2001-09-27 | 2005-11-01 | Kyorin Pharmaceutical Co., Ltd. | Diaryl sulfide derivative, addition salt thereof, and immunosuppressant |
WO2003029184A1 (fr) | 2001-09-27 | 2003-04-10 | Kyorin Pharmaceutical Co., Ltd. | Derive d'ether de diaryle, son sel d'addition et son immunosuppresseur |
CA2472715A1 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Edg receptor agonists |
ATE448193T1 (de) | 2002-01-18 | 2009-11-15 | Merck & Co Inc | ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß |
US20030213603A1 (en) | 2002-05-14 | 2003-11-20 | Fisher David B. | Dual use extension apparatus for a tool |
US7456155B2 (en) | 2002-06-28 | 2008-11-25 | Idenix Pharmaceuticals, Inc. | 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
GB0313444D0 (en) | 2003-06-11 | 2003-07-16 | Midland Medical Technologies L | Modular dysplasia cup |
GB0320638D0 (en) | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
SG139750A1 (en) | 2004-10-01 | 2008-02-29 | Debiopharm Sa Ch | Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3- [etval]4-cyclosporin |
NZ555143A (en) | 2004-12-23 | 2009-12-24 | Novartis Ag | Compositions for HCV treatment |
-
2003
- 2003-09-03 GB GBGB0320638.0A patent/GB0320638D0/en not_active Ceased
-
2004
- 2004-09-02 TW TW093126578A patent/TWI342782B/zh not_active IP Right Cessation
- 2004-09-02 PL PL04764762T patent/PL1663287T3/pl unknown
- 2004-09-02 DE DE602004022061T patent/DE602004022061D1/de active Active
- 2004-09-02 WO PCT/EP2004/009804 patent/WO2005021028A1/en active Application Filing
- 2004-09-02 CA CA2537137A patent/CA2537137C/en not_active Expired - Fee Related
- 2004-09-02 SI SI200431200T patent/SI1663287T1/sl unknown
- 2004-09-02 US US10/570,097 patent/US7968518B2/en active Active
- 2004-09-02 EP EP04764762A patent/EP1663287B1/en active Active
- 2004-09-02 RU RU2006110533/15A patent/RU2389501C2/ru not_active IP Right Cessation
- 2004-09-02 EP EP06125649.1A patent/EP1797892B1/en active Active
- 2004-09-02 SG SG200809555-6A patent/SG149063A1/en unknown
- 2004-09-02 AU AU2004268382A patent/AU2004268382A1/en not_active Abandoned
- 2004-09-02 DK DK04764762T patent/DK1663287T3/da active
- 2004-09-02 KR KR1020067004342A patent/KR101116968B1/ko active IP Right Grant
- 2004-09-02 CN CNA2004800246044A patent/CN1842343A/zh active Pending
- 2004-09-02 BR BRPI0414062A patent/BRPI0414062B8/pt not_active IP Right Cessation
- 2004-09-02 ES ES04764762T patent/ES2328361T3/es active Active
- 2004-09-02 MX MXPA06002394A patent/MXPA06002394A/es active IP Right Grant
- 2004-09-02 JP JP2006525712A patent/JP4688806B2/ja not_active Expired - Fee Related
- 2004-09-02 NZ NZ545495A patent/NZ545495A/en not_active IP Right Cessation
- 2004-09-02 PT PT04764762T patent/PT1663287E/pt unknown
-
2006
- 2006-02-22 ZA ZA200601550A patent/ZA200601550B/en unknown
- 2006-02-23 IL IL173909A patent/IL173909A/en active IP Right Grant
- 2006-03-02 TN TNP2006000071A patent/TNSN06071A1/en unknown
- 2006-03-10 MA MA28865A patent/MA28032A1/fr unknown
- 2006-03-24 IS IS8371A patent/IS2917B/is unknown
- 2006-03-31 NO NO20061479A patent/NO20061479L/no not_active Application Discontinuation
- 2006-11-09 HK HK06112329.1A patent/HK1091732A1/xx not_active IP Right Cessation
-
2008
- 2008-07-09 AU AU2008203031A patent/AU2008203031B2/en not_active Ceased
-
2009
- 2009-09-16 CY CY20091100955T patent/CY1110506T1/el unknown
- 2009-10-05 HR HR20090535T patent/HRP20090535T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20061479L (no) | Anvendelse av modifiserte cyklosporiner for behandling av HCV-forstyrrelser | |
NO20073765L (no) | Forbindelser for behandling av flaviviridae | |
MA30893B1 (fr) | Inhibiteurs de la protease ns3 du vhc | |
NO20073764L (no) | Sammensetninger for behandling av HCV | |
EA200702493A1 (ru) | Соединения и способы лечения или предотвращения флавивирусных инфекций | |
EP1924593B8 (en) | Hcv ns3 protease inhibitors | |
EA200901241A1 (ru) | Соединения для лечения гепатита с | |
NO20083694L (no) | Bruk av rylener som markorer for vaesker | |
NO20081086L (no) | Makrosykliske peptider som HCV NS3-proteaseinhibitorer | |
HK1108703A1 (en) | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection | |
NO20076502L (no) | Pyrrolopyridiner nyttige som inhibitorer av proteinkinase | |
MXPA05008126A (es) | Inhibidores de girasa y uso de los mismos. | |
WO2008051477A3 (en) | Hcv ns3 protease inhibitors | |
ECSP045191A (es) | "nuevos péptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c" | |
MXPA05012323A (es) | Sulfonamidas ciclicas para la inhibicion de gama-secretasa. | |
NO20055649L (no) | Substituert dihydrokinazolin med antiviale egenskaper | |
WO2005074598A3 (en) | Nitroxyl progenitor compounds and methods of use | |
EA201070423A1 (ru) | Диарильные соединения оксадиазолов | |
EA201000329A1 (ru) | Циклические депсипептиды | |
GT200600262A (es) | Uso de la sangliferina en el hcv (virus de la hepatitis "c") | |
NO20075815L (no) | Formuleringer og metoder for behandling av amyloidose | |
NO20076515L (no) | Hydantoinforbindelser | |
DE602006017574D1 (de) | Als protein-kinase-inhibitoren nutzbare benzimidazole | |
DK1373220T3 (da) | Benzimidazoler, som er nyttige ved behandling af seksuel dysfunktion | |
DE60317935D1 (de) | Alpha-aminoamid-derivate als mittel gegen migräne |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |